PMID: 20648098Jul 22, 2010Paper

Intensive care triage in Australia and New Zealand

The New Zealand Medical Journal
Paul J Young, Richard Arnold

Abstract

To compare the attitudes towards common intensive care triage scenarios in New Zealand and Australia and to evaluate Australasian intensive care triage practice. A web-based survey of Australian and New Zealand intensive care doctors measuring demographics, details of recent triage decisions and attitudes towards various triage scenarios. A total of 238 responses were obtained (32.6% response rate). The mean number of triage decisions was 6.3 per clinician per week in New Zealand (95%CI 4.6-8.0) and 8.5 per week in Australia (95% CI 6.6-10.4) (test for difference in means, p=0.08). The mean rate of refusal for the week prior to the survey was 30.8% (95%CI 19.5-42.1) among New Zealand respondents and 25.1% (95% CI 19.7-30.4) among Australian respondents (test for difference in proportions, p=0.35). Australian respondents were more likely than New Zealand respondents to agree that it was appropriate to admit a patient: - with a non-survivable brain injury who may progress to brain death (p=0.0001); - with acute respiratory distress syndrome in the setting of relapsed acute myeloid leukaemia (p=0.0005); - in a persistent vegetative state with pneumonia due to malposition of a feeding tube (p=0.03); However, there were no differenc...Continue Reading

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.